A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells
0301 basic medicine
Receptors, Chimeric Antigen
T-Lymphocytes
Interleukin-3 Receptor alpha Subunit
Mice, SCID
Immunotherapy, Adoptive
Xenograft Model Antitumor Assays
3. Good health
Leukemia, Myeloid, Acute
Mice
03 medical and health sciences
Mice, Inbred NOD
Cell Line, Tumor
Animals
Humans
DOI:
10.2217/imt-2021-0143
Publication Date:
2022-02-14T09:54:06Z
AUTHORS (10)
ABSTRACT
Aim: To investigate whether anti-CD123 chimeric antigen receptor (CAR)-expressing Vγ9Vδ2 T cells could be an alternative for acute myeloid leukemia (AML) treatment. Materials & methods:Ex vivo expanded were electroporated with CAR-encoding mRNA. The effector function and specificity of the modified examined by in vitro cytotoxicity, degranulation cytokine release level. was analyzed using xenograft KG1-luc model NOD-SCID-γc-/- mice. Results: exhibited significantly improved activities against both AML cell lines primary vitro. In mouse model, displayed enhanced tumor control potency. Conclusion: Anti-CD123 CAR-expressing may serve as way to target AML.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (46)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....